Globus Medical (NYSE:GMED) Issues FY 2026 Earnings Guidance

Globus Medical (NYSE:GMED) updated its FY 2026 earnings guidance on Thursday. The company provided EPS guidance of 4.950-5.050 for the period, compared to the consensus earnings per share estimate of 4.740. The company issued revenue guidance of $3.2 billion-$3.2 billion, compared to the consensus revenue estimate of $3.2 billion.

Analysts Set New Price Targets

GMED has been the subject of a number of research analyst reports. Truist Financial reduced their target price on Globus Medical from $115.00 to $100.00 and set a “buy” rating for the company in a research note on Thursday, July 16th. Wells Fargo & Company cut their price target on shares of Globus Medical from $103.00 to $99.00 and set an “overweight” rating on the stock in a report on Friday. Royal Bank Of Canada reduced their price target on shares of Globus Medical from $120.00 to $115.00 and set an “outperform” rating for the company in a research report on Monday, July 13th. Zacks Research downgraded shares of Globus Medical from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. Finally, UBS Group began coverage on shares of Globus Medical in a report on Tuesday, July 28th. They set a “neutral” rating and a $82.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $101.77.

Globus Medical Price Performance

NYSE:GMED traded up $1.12 during trading hours on Friday, reaching $82.20. The company had a trading volume of 3,299,652 shares, compared to its average volume of 1,551,427. Globus Medical has a 1-year low of $54.15 and a 1-year high of $101.40. The firm has a market cap of $11.16 billion, a PE ratio of 21.02, a price-to-earnings-growth ratio of 1.67 and a beta of 0.95. The business’s 50 day moving average price is $79.33 and its 200-day moving average price is $85.23.

Globus Medical (NYSE:GMED) last issued its quarterly earnings data on Thursday, August 6th. The medical device company reported $1.34 EPS for the quarter, topping analysts’ consensus estimates of $1.10 by $0.24. The business had revenue of $789.61 million for the quarter, compared to analysts’ expectations of $782.88 million. Globus Medical had a net margin of 17.02% and a return on equity of 14.73%. The business’s revenue was up 5.9% on a year-over-year basis. During the same quarter last year, the company earned $0.86 EPS. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. On average, analysts expect that Globus Medical will post 4.74 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director David D. Davidar sold 25,000 shares of the firm’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the sale, the director owned 510,175 shares in the company, valued at approximately $41,201,733. This trade represents a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 18.38% of the company’s stock.

Globus Medical News Roundup

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Q2 results exceeded expectations: Globus Medical reported adjusted earnings of $1.34 per share, ahead of the approximately $1.10–$1.12 consensus, while revenue reached $789.6 million versus estimates of $782.9 million. Revenue increased 5.9% year over year, and EPS rose substantially from $0.86 in the prior-year quarter. Globus Medical Q2 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Profit outlook improved: Management raised its fiscal 2026 EPS guidance to $4.95–$5.05, above the prior analyst consensus of $4.74. The earnings call highlighted margin gains, spine-market growth and continued benefits from operating leverage. GMED Q2 Earnings Call Highlights
• Positive Sentiment: Analyst support remains favorable: TD Cowen maintained a Buy rating and a $115 price target, citing reaccelerating spine growth, strong earnings power and robust research-and-development investment. Globus Medical Earns Buy Rating
• Neutral Sentiment: Sales outlook was unchanged: Globus Medical kept fiscal 2026 revenue guidance near $3.2 billion, roughly in line with consensus. This limits the upside from the earnings report but indicates management is maintaining its growth expectations.
• Negative Sentiment: Some execution risks remain: Management cited risks involving Nevro and Enabling Technologies, contributing to caution around revenue growth. Wells Fargo also lowered its price target from $103 to $99, although it retained an Overweight rating. Wells Fargo Analyst Action

Institutional Investors Weigh In On Globus Medical

Institutional investors have recently modified their holdings of the business. Advisory Services Network LLC purchased a new position in Globus Medical during the third quarter worth approximately $26,000. EverSource Wealth Advisors LLC increased its position in shares of Globus Medical by 74.3% in the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after buying an additional 197 shares in the last quarter. Parallel Advisors LLC raised its stake in shares of Globus Medical by 45.1% during the 3rd quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock worth $32,000 after buying an additional 173 shares during the period. Headlands Technologies LLC raised its stake in shares of Globus Medical by 485.4% during the 2nd quarter. Headlands Technologies LLC now owns 761 shares of the medical device company’s stock worth $45,000 after buying an additional 631 shares during the period. Finally, Hollencrest Capital Management purchased a new position in shares of Globus Medical during the 4th quarter valued at approximately $51,000. 95.16% of the stock is currently owned by institutional investors and hedge funds.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.